February 2008- Global Vaccines is recognized for working to help bring vaccines to the developing world.   Universities Allied for Essential Medicines (UAEM), a non-profit organization that advocates increased neglected disease research in university laboratories and improved access to health technologies in developing countries, has highlighted Global Vaccines, Inc., because of the company’s model for improving new vaccine technologies that can be distributed at low cost in the developing world. UAEM believes that Global Vaccines and other innovative product development partnerships play a critical role in addressing the unmet needs of those in the developing world.  Read the entire press release here.

January 2008- Global Vaccines sub-licenses AutheniForm technologies for humanitarian use.  Global Vaccines sub-licensed from AuthentiForm Technologies, L.L.C., the humanitarian-use rights to AuthentiForm’s intellectual property portfolio of enhanced product-authentication technology. Global plans to use the product-authentication technology in conjunction with its current and future vaccines.  Read the entire press release here.

October 2007- Global Vaccines completes expansion into new lab and office space.  As Global Vaccines has grown in both funding and personnel, we have expanded into 4,000 square feet of lab and office space.  This new space is all housed within the Alexandria Innovation Center, a biotechnology incubator building, located at 7020 Kit Creek Road in the North Carolina Research Triangle Park. (see photos)

July 2007- Global Vaccines meets its year-one milestones for the T-Cell Vaccine Research and Development Consortium.  In July 2006 Global Vaccines was awarded milestone-driven funding through its membership in the International AIDS Vaccine Initiative's T-Cell Vaccine Research and Development Consortium.  This Consortium is one of 11 consortia that make up The Collaboration for AIDS Vaccine Discovery (CAVD).  "The CAVD is an international network of eleven Vaccine Discovery Consortia (VDCs) and five Central Service Facilities (CSFs) funded by the Bill & Melinda Gates Foundation to apply new technologies, concepts and approaches to the design of safe and effective preventive vaccines against HIV/AIDS."  

October 2006- Global Vaccines enters shared use agreement with the University of North Carolina.  The University of North Carolina at Chapel Hill (UNC-CH) and Global Vaccines have entered into an agreement that will allow Global Vaccines to use the newly constructed state-of-the-art BSL-3 laboratories at UNC-CH.  This agreement is a clear indication of the University’s support of Global Vaccines and the spirit of combining resources held by both UNC-CH and Global Vaccines to move vaccine research forward.

September 2006- Global Vaccines awarded grant from NIH to study new adjuvant technology.  Global Vaccines has been awarded a $5.3 million grant from the National Institutes of Health for a four-year study of Global Vaccines’ novel vaccine adjuvant technology.  This grant will enable an in-depth study of the adjuvant effect and the determination of its utility in nonhuman primates. One of the grant reviewers stated that the technology “represents a significant advance in the field of vaccination.” A manuscript describing the technology has been published in the Proceedings of the National Academy of Sciences (volume 103, pp 3722-3727, 2006)

July 2006- Global Vaccines receives additional funding from IAVI.  The International AIDS Vaccine Initiative has received a $23.7 million award from the Bill & Melinda Gates Foundation to pursue novel viral vectors through the T-Cell Vaccine Research and Development Consortium. Global Vaccines is a member of this consortium and will receive $1.7 million annually for five years (through 2011).  The purpose of the T-Cell Consortium is “to study a range of novel viral vectors that have been identified as promising for their potential use in HIV vaccines, but have not been adequately pursued to date.”

 

February 2006- Global Vaccines licenses two new technologies.  Global Vaccines has licensed two technologies from the University of North Carolina, Chapel Hill. The first is a new type of biological adjuvant designed to greatly enhance both systemic and mucosal immunity when used in combination with inexpensive killed virus and subunit vaccines. This technology has the capability of decreasing cost by a factor of ten or greater, increasing the effectiveness of some existing vaccines, and making other vaccines possible.
The second technology describes creating new, live-attenuated vaccines from scratch. GVI is applying this to the creation of a new type of vaccine for HIV, specifically for the strain of the virus circulating in sub-Saharan Africa.

December 2005- Global Vaccines awarded funding from the International Aids Vaccine Initiative.  Global Vaccines has been awarded a milestone-driven grant from the International AIDS Vaccine Initiative (IAVI) that extends until 2012 with a budget of $1.2 million for the first two years.  IAVI has invited Global vaccines to join its “Neutralizing Antibody Consortium” (NAC).  According to its website, the NAC “was established by IAVI to address one of the field's most critical scientific challenges: designing vaccines to induce broadly neutralizing antibodies against HIV, which would be capable of blocking infection by a wide range of HIV isolates circulating worldwide. The NAC comprises several internationally recognized scientific laboratories, complemented by core resources to enable screening of leading vaccine designs. Member institutions include: Cornell University; Dana-Farber Cancer Institute; Global Vaccines Inc.; Harvard University; Institute of Research in Biomedicine; The Scripps Research Institute; University of Pennsylvania; University of Wisconsin; and the University of Washington."